AgomAb Therapeutics NV ADR Dossier
Qualitative Analysis
Business overview
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel, disease-modifying therapies for fibro-inflammatory and inflammatory diseases. The company's scientific approach leverages growth factor biology to resolve fibrosis, repair tissue structure, and restore organ function. Its pipeline consists of organ-restricted small molecules and monoclonal antibodies designed to target established biological pathways (such as TGF-Β/ALK5 and HGF/cMET) while minimizing systemic toxicities. Agomab retains exclusive, worldwide development and commercialization rights to all of its product candidates.
Research as of 24 Jul 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Developing small molecule inhibitors designed to target specific organs (such as the gut or lungs) to avoid systemic toxicities associated with TGF-beta pathway inhibition.
Expected impact: Aims to deliver first-in-class, disease-modifying therapies for fibrostenosing Crohn's disease and idiopathic pulmonary fibrosis with superior safety profiles.
Advancing the clinical development of the pipeline, including initiating the Phase 2b NOV-ERA study for ontunisertib and a Phase 2 study for AGMB-447, alongside preparing AGMB-101 (a MET receptor agonist) for Phase 1 clinical trials in liver cirrhosis.
Expected impact: Establishes a robust, multi-asset clinical-stage portfolio addressing high unmet medical needs in fibro-inflammatory diseases.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of Origo Biopharma brought in the key ALK5 small molecule inhibitors (ontunisertib and AGMB-447) into Agomab's pipeline, establishing its core focus on TGF-beta pathway inhibition.
Financial impact: Shifted Agomab's strategic focus toward small-molecule TGF-β pathway inhibitors, attracting major pharmaceutical backers like Pfizer, Sanofi, and Boehringer Ingelheim.
Strategic Partnerships
Sanofi participated in Agomab's Series D financing round and acquired a significant equity stake, validating Agomab's pipeline and providing strategic backing.
Terms: Sanofi acquired 2,783,096 shares at $10.49 per share on March 31, 2026, representing a major holding in its investment portfolio.
Pfizer led a $40.5 million extension to Agomab's Series B financing round, providing strategic validation and backing for Agomab's organ-restricted ALK5/TGF-β platform.
Terms: Part of the Series B extension round.